Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Each four-week block matters
Discontinued formulations Efpeglenatide and taspoglutide Efpeglenatide and taspoglutide were once-promising, long-acting GLP-1 receptor agonists developed for the treatment of T2DM, both designed for once-weekly administration
They can advise based on the specific duration and temperature of the excursion
Injection-site and quality risks Rotating sites between abdomen, thigh, and upper arm is a common practice to avoid lipohypertrophy
Trends in first-time prescribing First-time prescribing rates (first-time GLP-1 RA prescriptions per total prescriptions) in September 2024 are about the same as rates in June 2024 (- 1.6%)
Match the vial to the weekly dose and realistic post-reconstitution use
US$ 22.69
US$ 21.05
US$ 23.71
US$ 20.83
US$ 28.01
US$ 26.39
US$ 26.21
US$ 23.79
